EGFR and NSCLC Diagnostic Strategies: What Should You Know?

This live event has already occurred. The archived version of this activity will be available here within the next few weeks.

EGFR mutation status is important at the time of diagnosis of NSCLC and in patients whose disease has become refractory to EGFR tyrosine kinase inhibitors (TKIs). In both settings, mutation status can help direct treatment. The most common mechanism of tumor resistance to EGFR TKIs is the EGFR exon 20 p. T790M mutation. An emerging area of interest is the ability of liquid biopsy to detect activating EGFR mutations and to detect T790M EGFR mutations at the time of relapse. Understanding the latest developments in this field should help physicians provide the best care for their patients with NSCLC.

Join us on November 9, 2016, at 12:00 pm EST for a live, web-based CME event from the Association for Molecular Pathology 2016 Annual Conference in Charlotte, North Carolina, where an expert panel will discuss the importance of identifying EGFR mutations and testing for EGFR resistance mechanisms in patients with NSCLC and the latest biopsy techniques.

	Laura J. Tafe, MD Assistant Professor of Pathology Assistant Director Laboratory for Clinical Genomics and Advanced Technology Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire
	Jared Weiss, MD Assistant Professor Division of Hematology-Oncology Thoracic Oncology Program University of North Carolina-Chapel Hill
	Chad A. Livasy, MD Carolinas Pathology Group Carolinas Medical Center Adjunct Professor University of North Carolina-Chapel Hill

Prior to the live webcast event, please check that your system requirements allow you to view the program:

• Open the following URL: Click to perform System Check

If you are unable to access this test event, please contact your IT department for additional assistance.